Dupilumab in a 9-week-old with Netherton Syndrome Leads to Deep Symptom Control

Due to the high complication rate of NS, especially in the first years of life, we recommend treatment with dupilumab off-label immediately after the diagnosis has been established.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Immunology
Published
2024-11-15
DOI
https://doi.org/10.1007/s10875-024-01837-z
Citations
5
Primary Topic
Skin and Cellular Biology Research
Type
article
Field-Weighted Citation Impact
1.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dupilumab in a 9-week-old with Netherton Syndrome Leads to Deep Symptom Control

Fabian Hauck, Franziska Sattler, Narjes Abdulhameed Alelq, Susanne M. Schmidt et al.
5 citations
Journal of Clinical Immunology
Skin and Cellular Biology Research
1.63
article

Dupilumab in a 9-week-old with Netherton Syndrome Leads to Deep Symptom Control

Fabian Hauck, Franziska Sattler, Narjes Abdulhameed Alelq, Susanne M. Schmidt, Yannik Vollmuth
article en
5 citations

Abstract

Due to the high complication rate of NS, especially in the first years of life, we recommend treatment with dupilumab off-label immediately after the diagnosis has been established.

Journal of Clinical ImmunologyVol. 45(1)
LMU Klinikum (DE), Ministry of Health (SA), Ludwig-Maximilians-Universität München (DE)
Good health and well-being
Openalex Percentile: Top 17%
Skin and Cellular Biology Research
1.63
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.